No profile data available.
Alterity Therapeutics Limited (ATHE) is a healthcare company in the brain and nerve treatment drugs industry, based in Melbourne, Australia, with about 11 full-time employees.
It reported revenue of 0 AUD for fiscal year 2025, and net income of -12.15 million AUD. Its market capitalization was $56.72 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Alterity Therapeutics reported 0 AUD in revenue for fiscal year 2025.
$56.72 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Gain Therapeutics, Inc. (GANX), Cingulate Inc. (CING), Mira Pharmaceuticals, Inc. (MIRA), Annovis Bio, Inc. (ANVS).